quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:00:00·31d
PRRelease
Aurinia Pharmaceuticals Inc logo

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

AUPH· Aurinia Pharmaceuticals Inc
Health Care
Original source

Companies

  • AUPH
    Aurinia Pharmaceuticals Inc
    Health Care

Recent analyst ratings

  • Dec 3UpdateLeerink Partners$16.00
  • Nov 7UpdateJefferies$21.00
  • Nov 5UpdateRBC Capital Mkts$15.00
  • Jul 30UpdateH.C. Wainwright$17.00
  • Nov 4UpdateOppenheimer-
  • May 5UpdateCantor Fitzgerald$25.00

Related

  • SEC2d
    SEC Form DEF 14A filed by Aurinia Pharmaceuticals Inc
  • SEC20d
    Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
  • INSIDER21d
    SEC Form 3 filed by new insider Cole Ryan
  • INSIDER21d
    SEC Form 3 filed by new insider Hearne Michael S
  • PR24d
    Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
  • SEC29d
    Amendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals Inc
  • SEC31d
    Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR31d
    Aurinia Announces Management Transition
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022